A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...

Grünenthal has appointed Jan Adams as its new chief commercial officer, effective October 1. Dr. Adams, currently the chief ...

Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research ...

India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...

Global leaders at the 79th UN General Assembly approved a political declaration on antimicrobial resistance (AMR), targeting ...

China's top drug regulator, says it will redouble efforts to facilitate research and market registration of homegrown innovative drugs, while speeding up the introduction of novel foreign drugs to the ...

China-based Asieris Pharmaceuticals announced that the international multicenter Phase III clinical study data of its ...

The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

The US Food and Drug Administration (FDA) granted traditional approval for US pharma major Eli Lilly’s Retevmo (selpercatinib ...